Day: November 17, 2025

VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) — Scope Technologies Corp. (CSE: SCPE | OTC: SCPCF | FSE: VN8) (“Scope Technologies” or the “Company”) is pleased to announce that it has successfully achieved Level 2 Certification under the CyberSecure Canada program (CSCC), administered by Cyber Security Canada (CSC) and recognized by the Standards Council of Canada (SCC). Building on its Level 1 certification earned in September 2025, this milestone demonstrates Scope’s continued advancement in verified cybersecurity maturity. The Level 2 Certification, combined with the Company’s team of CSP-accredited professionals, enables Scope Technologies to engage government stakeholders at all levels of project clearance classifications—up to and including Secret Level on cybersecurity-related projects. Certification Significance...

ProVen VCT plc (LEI: 21380091P1TTU2Z2AW75)        ProVen Growth and Income VCT plc (LEI: 213800K1RM776QM8XG84)(together the “Companies” and each being a “Company”)         17 November 2025         Publication of Prospectus The Companies announce that they have today published a Prospectus (comprising a Securities Note, Registration Document and Summary) in respect of an offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies (“New Ordinary Shares”), with an over-allotment facility of up to a further £10,000,000 in aggregate (each Company raising a maximum of £20,000,000 including the over-allotment facility), payable in full in cash on application (the “Offer”). The Offer opens on 17 November 2025 and will close not later than 12 p.m....

ProVen VCT plc (LEI: 21380091P1TTU2Z2AW75)        ProVen Growth and Income VCT plc (LEI: 213800K1RM776QM8XG84)(together the “Companies” and each being a “Company”)         17 November 2025         Publication of Prospectus The Companies announce that they have today published a Prospectus (comprising a Securities Note, Registration Document and Summary) in respect of an offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies (“New Ordinary Shares”), with an over-allotment facility of up to a further £10,000,000 in aggregate (each Company raising a maximum of £20,000,000 including the over-allotment facility), payable in full in cash on application (the “Offer”). The Offer opens on 17 November 2025 and will close not later than 12 p.m....

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) —  Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM. “Too many patients living with HCM face a lack of awareness about their...